Jun 2026 (Q2 FY26) — Aug 6, 2026
Novanta Q2 FY26 — Strong Organic Growth and Transformative Acquisition
Read the full callNovanta (NOVT) earnings
- Jul 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Novanta earnings: last reported Thu, 6 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 266 | +10.3% YoY | Quarterly, as filed | Quarter to Jul 2026 | Revenue from operations as filed. |
| Operating margin | 6.8 | +0.6 pts YoY | Operating profit / revenue | Quarter to Jul 2026 | For the quarter; a change is in percentage points. |
| Net profit | 12.5 | +178.9% YoY | Quarterly, as filed | Quarter to Jul 2026 | Profit after tax as filed. |
Price
$131.52 +2.12% · +$2.73
Performance +24.6% 1Y
1Y: $105.56 on 17 Oct 2025 → $131.52. High $168.75 (17 Aug 2026), low $99.22 (20 Nov 2025).
- Previous close
- $128.79
- 52-week range
- $99.22 – $168.75
- One year
- +21.29%
Overview
- Symbol
- NOVT
- Sector
- Information Technology
- Exchange
- US
- Currency
- USD
Call summaries
Mar 2026 (Q1 FY26) — May 12, 2026
Novanta Q1 FY26 — Strong Bookings and Organic Growth Acceleration
Read the full callDec 2025 (Q4 FY25) — Feb 24, 2026
Novanta Q4 FY25 — Strong Bookings and Organic Growth Return, AI Tailwinds Emerging
Read the full callEvery analysed call
Novanta earnings calls (NOVT)
Financials
What the filings say
Net profit, year on year: +179% (quarter to jul 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Apr 2026 | Jul 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 244 | 238 | 233 | 241 | 248 | 258 | 258 | 266 |
| Operating profit | 33 | 27 | 32 | 15 | 22 | 25 | 28 | 18 |
| Operating margin | 13.3% | 11.2% | 13.9% | 6.2% | 8.8% | 9.6% | 10.7% | 6.8% |
| Profit before tax | 24 | 21 | 26 | 6 | 16 | 22 | 26 | 16 |
| Tax rate | 20.8% | 20.8% | 19.7% | 22.3% | 32.4% | 19.4% | 19.9% | 21.1% |
| Net profit | 19 | 16 | 21 | 4 | 11 | 17 | 21 | 13 |
| EPS ($ per share) | 0.53 | — | 0.59 | 0.12 | 0.30 | — | 0.52 | 0.31 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 424 | 424 | 424 | 424 | 424 | 424 | 424 | 424 |
| Reserves | -79 | -38 | 6 | 57 | 131 | 203 | 268 | 321 |
| Total liabilities | 351 | 453 | 388 | 707 | 664 | 553 | 643 | 493 |
| Fixed assets | 65 | 78 | 79 | 87 | 103 | 109 | 113 | 118 |
| Total assets | 720 | 870 | 865 | 1,228 | 1,241 | 1,226 | 1,389 | 1,807 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 90 | 63 | 140 | 95 | 91 | 120 | 159 | 64 |
| Cash from investing | -46 | -64 | -13 | -307 | -43 | -20 | -208 | -74 |
| Cash from financing | -60 | -4 | -84 | 205 | -60 | -98 | 57 | 276 |
| Net cash flow | -18 | -3 | 46 | -8 | -17 | 5 | 9 | 267 |
| Capital expenditure | -15 | -11 | -11 | -20 | -20 | -20 | -17 | -16 |
| Free cash flow | 75 | 53 | 130 | 75 | 71 | 100 | 141 | 48 |
NOVT operating KPIs by quarter
| KPI | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|
| Book-to-bill | 1.11 ratioBookings surged 25% year-over-year and 12% sequentially with a book-to-bill of 1.11.Source: earnings call transcript | 1.1 ratioBookings grew 37% year-over-year with a book-to-bill of 1.10 on continued new product momentum and strong commercial execution.Source: earnings call transcript | — | -0.9% |
| Vitality Index | 24%New product sales in the fourth quarter grew over 80% year-over-year, raising the Vitality Index to 24% of sales.Source: earnings call transcript | 27%In addition, new product sales grew over 50% year-over-year, raising the Vitality Index to 27% of sales.Source: earnings call transcript | ~29%New product revenue grew by more than 50% in the quarter and is up over 60% year-to-date, lifting our vitality index to approximately 29% of sales from 21% a year ago.Source: earnings call transcript | — |
| Book-to-bill Automation Enabling Technologies | 1.16 ratioThe book-to-bill in this segment was 1.16 and bookings were up 33% year-over-year.Source: earnings call transcript | 1.15 ratioThe book-to-bill in this segment was 1.15 and bookings were up 35% year-over-year.Source: earnings call transcript | 1.1 ratioThe book-to-bill in this segment was 1.1 and bookings were up 18% year-over-year.Source: earnings call transcript | -4.3% |
| Book-to-bill Medical Solutions | 1.07 ratioThis segment saw a book-to-bill of 1.07 in the fourth quarter and bookings were up 17% year-over-year.Source: earnings call transcript | 1.04 ratioThis segment saw a book-to-bill of 1.04 in the quarter and bookings were up 40% year-over-year.Source: earnings call transcript | 0.79 ratioThis segment saw a book-to-bill of 0.79 in the second quarter and year-to-date had bookings growth of greater than 10% year-over-year.Source: earnings call transcript | -24% |
| Vitality Index Medical Solutions | <28%New product sales in the fourth quarter grew by nearly 80% year-over-year and the Vitality Index in this segment was nearly 28% of sales.Source: earnings call transcript | — | 30%+New product sales grew by nearly 50% year-over-year and the vitality index in this segment was above 30% of sales.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Insider filings
87 filings between Dec 2, 2025 and Sep 11, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$11.57M
45 sales by 3 insiders
100% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 25
- Option exercise — converted options into shares
- 15
- Tax withheld — shares kept back by the company to cover tax
Also filed: 2 gifts.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Glastra Matthijs | — | $9.73M | Jul 2, 2026 |
| Buckley Robert | — | $1.56M | Mar 16, 2026 |
| Secor Thomas N | — | $277.1K | Sep 11, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 11, 2026 | Secor Thomas N Director | Sale 10b5-1 plan | 663 | $97.9K |
| Jul 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 1,672 | $269.7K |
| Jul 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 3,024 | $484.2K |
| Jul 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 1,167 | $189.1K |
| Jul 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 200 | $32.8K |
| Jul 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 437 | $71.5K |
| Jun 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 500 | $83.1K |
| Jun 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 38 | $6.3K |
| Jun 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 400 | $68.5K |
| Jun 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 1,301 | $220.9K |
| Jun 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 2,841 | $479.4K |
| Jun 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 1,420 | $238.1K |
| May 12, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 5,079 | $761.9K |
| May 12, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 2,421 | $366.4K |
| May 5, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 1,022 | $134.6K |
| May 5, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 23 | $3.1K |
| May 5, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 1,180 | $156.4K |
| May 5, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 4,275 | $558.3K |
| Apr 17, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 6,500 | $845.3K |
| Mar 16, 2026 | Buckley Robert Chief Financial Officer | Option exercise 10b5-1 plan | 9,957 | $140.7K |
| Mar 16, 2026 | Buckley Robert Chief Financial Officer | Sale 10b5-1 plan | 86 | $10.2K |
| Mar 16, 2026 | Buckley Robert Chief Financial Officer | Sale 10b5-1 plan | 1,937 | $228.1K |
| Mar 16, 2026 | Buckley Robert Chief Financial Officer | Sale 10b5-1 plan | 4,719 | $551.4K |
| Mar 16, 2026 | Buckley Robert Chief Financial Officer | Sale 10b5-1 plan | 3,215 | $373.0K |
| Mar 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 1,180 | $164.6K |
| Mar 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 940 | $130.3K |
| Mar 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 1,375 | $188.8K |
| Mar 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 586 | $79.9K |
| Mar 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 500 | $66.9K |
| Mar 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 1,796 | $252.3K |
| Mar 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 74 | $10.0K |
| Mar 2, 2026 | Glastra Matthijs Chief Executive Officer | Sale 10b5-1 plan | 49 | $6.5K |
| Feb 24, 2026 | Glastra Matthijs Chief Executive Officer | Tax withheld | 5,247 | $721.1K |
| Feb 24, 2026 | Glastra Matthijs Chief Executive Officer | Option exercise | 10,852 | — |
| Feb 24, 2026 | Ravetto Charles Guy JR Co-Chief Operating Officer | Tax withheld | 243 | $33.4K |
| Feb 24, 2026 | Ravetto Charles Guy JR Co-Chief Operating Officer | Option exercise | 825 | — |
| Feb 24, 2026 | Burke John Joseph II Chief Accounting Officer | Tax withheld | 141 | $19.4K |
| Feb 24, 2026 | Burke John Joseph II Chief Accounting Officer | Option exercise | 479 | — |
| Feb 24, 2026 | Buckley Robert Chief Financial Officer | Tax withheld | 2,624 | $360.6K |
| Feb 24, 2026 | Buckley Robert Chief Financial Officer | Option exercise | 5,426 | — |
| Feb 23, 2026 | Ravetto Charles Guy JR Co-Chief Operating Officer | Tax withheld | 311 | $44.3K |
| Feb 23, 2026 | Ravetto Charles Guy JR Co-Chief Operating Officer | Option exercise | 1,059 | — |
| Feb 23, 2026 | Burke John Joseph II Chief Accounting Officer | Option exercise | 519 | — |
| Feb 23, 2026 | Burke John Joseph II Chief Accounting Officer | Tax withheld | 176 | $25.1K |
| Feb 20, 2026 | Buckley Robert Chief Financial Officer | Option exercise 10b5-1 plan | 2,450 | — |
| Feb 20, 2026 | Glastra Matthijs Chief Executive Officer | Tax withheld | 2,574 | $375.7K |
| Feb 20, 2026 | Glastra Matthijs Chief Executive Officer | Option exercise | 5,322 | — |
| Feb 20, 2026 | Ravetto Charles Guy JR Co-Chief Operating Officer | Tax withheld | 480 | $70.1K |
| Feb 20, 2026 | Ravetto Charles Guy JR Co-Chief Operating Officer | Option exercise | 1,633 | — |
| Feb 20, 2026 | Lesica John Co-Chief Operating Officer | Tax withheld | 480 | $70.1K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for NOVANTA INC
Free account. Everything above stays public.
Write why you follow NOVANTA INC and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading